Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03108131 · OUTCOME

Disease Control Rate (DCR)

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors · Source last updated 2025-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
3 years

What was measured

Disease Control Rate (DCR) includes patients with tumor maintained at Stable Disease (SD), Partial Response (PR) and Complete Response (CR).

Groups in this outcome

Small Bowel Adenocarcinoma

Must be refractory or intolerant to at least one line of 5FU-based chemotherapy for metastatic disease and must not have clinically symptomatic malignant small bowel obstruction. Cobimetinib (60 mgorally once daily for days 1 - 21) and atezolizumab (840 mg intravenously every 2 weeks) every 28-day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Small Bowel Adenocarcinoma20

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Small Bowel Adenocarcinoma45Not reported23.168.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        23.1
        upper Limit
        68.5
        value
        45
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
Disease Control Rate (DCR) includes patients with tumor maintained at Stable Disease (SD), Partial Response (PR) and Complete Response (CR).
dispersion Type
95% Confidence Interval
groups
  1. description
    Must be refractory or intolerant to at least one line of 5FU-based chemotherapy for metastatic disease and must not have clinically symptomatic malignant small bowel obstruction. Cobimetinib (60 mgorally once daily for days 1 - 21) and atezolizumab (840 mg intravenously every 2 weeks) every 28-day cycle.
    id
    OG000
    title
    Small Bowel Adenocarcinoma
param Type
NUMBER
reporting Status
POSTED
time Frame
3 years
title
Disease Control Rate (DCR)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice